ロード中...
Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia in the chronic phase (CML-CP). However, it is unlikely that they can completely “cure” the disease. This might be because some subpopulations of CML-CP cells such as stem and progenitor cells are resistant to...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6826736/ https://ncbi.nlm.nih.gov/pubmed/31614827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101544 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|